AIA
BBH icon

Allegis Investment Advisors’s VanEck Biotech ETF BBH Stock Holding History

Allegis Investment Advisors’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-10
Closed -$1K – 253
2015
Q4 		$1K Buy
+10
New +$1.23K ﹤0.01% 1044

Other funds holding BBH

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LFM
Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Allegis Investment Advisors's BBH Position: Q1 2016 in Review

Allegis Investment Advisors sold out of VanEck Biotech ETF (BBH) in Q1 2016, closing a stake of 10 shares — an estimated $1K sold.

Allegis Investment Advisors first reported a position in BBH in Q4 2015 and held it in 1 quarter. The position peaked at $1K in Q4 2015. 71 funds tracked by Wall St. Rank hold BBH as of Q1 2016.

  • Allegis Investment Advisors reported no remaining VanEck Biotech ETF position as of Q1 2016 after selling out during the quarter.
  • Allegis Investment Advisors sold 10 VanEck Biotech ETF shares in Q1 2016, an estimated $1K.
  • Allegis Investment Advisors first reported a position in VanEck Biotech ETF in Q4 2015 and held it in 1 quarter.
  • Allegis Investment Advisors's VanEck Biotech ETF position peaked at $1K in Q4 2015.
  • 71 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2016.

Based on Allegis Investment Advisors's 13F filing for Q1 2016, filed 9 May 2016.